Metraipolis › archive › dc_779cd06f5a10

Primary Tumor Size and Tumor-Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor — Europe PMC PMID:41744875

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41744875
DOI
10.3390/curroncol33020111
License (as archived)
solo-consultazione
Archived
2026-11-05T21:51:36.457Z
SHA-256 of the archived text
c5bc0cea6812c062da256d3ded0f9086538b9cd7d05ec802984c72a18a2bd92f
Stable URL of this page
https://metraipolis.com/documento/dc_779cd06f5a10

How to cite

Primary Tumor Size and Tumor-Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor — Europe PMC PMID:41744875 — Europe PMC (en), https://europepmc.org/article/MED/41744875 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_779cd06f5a10 (Metraipolis archive dc_779cd06f5a10, sha256 c5bc0cea6812c062da256d3ded0f9086538b9cd7d05ec802984c72a18a2bd92f)
BibTeX
@misc{dc779cd06f5a10,
  title = {Primary Tumor Size and Tumor-Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor — Europe PMC PMID:41744875},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41744875},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_779cd06f5a10; sha256 c5bc0cea6812c062da256d3ded0f9086538b9cd7d05ec802984c72a18a2bd92f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41744875. Agents can read the archived copy with the MCP tool read_document.